PHARMA INDUSTRY TURNS TO AI FOR DRUG DEVELOPMENT

The pharmaceutical industry is increasingly adopting AI-driven approaches to streamline drug development processes. According to discussions between industry leaders, including Pradeep Bandaru, Head of Platforms & AI Workflows at Sanofi, and Shawn Rosemarin, Global VP of Research & Development at Everpure, data quality and accessibility are critical factors in this transformation. AI systems can process vast amounts of research data to identify promising drug candidates and predict outcomes more efficiently than traditional methods. This capability reduces development timelines and costs while improving success rates in clinical trials. The shift reflects broader industry recognition that computational approaches complement traditional pharmaceutical research. Companies investing in AI platforms and data infrastructure are positioning themselves to compete more effectively in drug discovery. As data becomes more sophisticated and AI models improve, pharmaceutical firms expect accelerated innovation cycles and better outcomes for patients awaiting new treatments.